{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Milestone Pharmaceuticals, Inc.
Is Milestone Pharmaceuticals, Inc. overvalued or undervalued?
As of May 13, 2024, Milestone Pharmaceuticals, Inc. is considered overvalued and has been downgraded to "does not qualify" due to negative financial metrics, including a Price to Book Value of -15.11 and a year-to-date return of -25.42%, significantly underperforming compared to the S&P 500.
Is Milestone Pharmaceuticals, Inc. technically bullish or bearish?
As of June 17, 2025, Milestone Pharmaceuticals, Inc. shows a mildly bullish trend supported by weekly MACD, KST, and RSI indicators, despite daily moving averages indicating a slightly bearish sentiment.
What does Milestone Pharmaceuticals, Inc. do?
Milestone Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing etripamil for cardiovascular treatments. As of March 2025, it has a market cap of $92.49 million and reported a net profit loss of $21 million.
How big is Milestone Pharmaceuticals, Inc.?
As of Jun 18, Milestone Pharmaceuticals, Inc. has a market capitalization of 92.49 million, with net sales of 0.00 million and a net profit of -51.92 million over the last four quarters. The company's shareholder's funds are 13.15 million, and total assets are 75.50 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
